Anbio Biotechnology Class A (NNNN) AI Stock Analysis

Anbio Biotechnology provides in vitro diagnostics (IVD) products across the European Union, Asia Pacific, North America, South America, and international markets. Incorporated in 2021 and headquartered in Frankfurt am Main, Germany, the company employs 27 people. Its product catalog includes lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions. In addition, Anbio offers SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. The company markets these diagnostic tools to over-the-counter, point-of-care testing, and laboratory customers globally.

Between FY2021 and FY2025, Anbio achieved a revenue compound annual growth rate of 18.2%. Revenue reached a peak of $23.5M in FY2022 before declining 71.5% to $6.7M in FY2023. Annual sales rebounded to $8.2M in FY2024 and grew 5.6% to $8.6M in FY2025. Gross margin expanded from 57.4% in FY2021 to 87.2% in FY2025, while operating margin rose to 66.7%. Net income for FY2025 reached $6.4M, reflecting a net margin of 74.1%. In the latest quarter ended March 31, 2026, quarterly revenue grew 73.9% year over year, while quarterly earnings grew 2.8% year over year.

As of March 31, 2026, Anbio held $11.9M in cash and short-term investments, with total assets of $30.2M and shareholders' equity of $30.2M. The company reported a current ratio of 344.31. Operating cash flow was -$6.7M in FY2025, resulting in free cash flow of -$6.7M, compared to positive operating cash flow of $2.1M in FY2024. Research and development expenses were $201,305 in FY2025, down from $454,227 in FY2024.

NNNN trades at a trailing price-to-earnings ratio of 20.9x, compared to the median of 24.6x for its US-listed Healthcare peers. Its enterprise value to EBITDA multiple of 44.4x sits well above the US-listed Healthcare peer median of 12.0x, and its price-to-sales ratio of 15.9x exceeds the peer median of 4.1x. The company's enterprise value is $256.3M against a market capitalization of $137.4M. Over the past year, NNNN shares fell 88.7%, lagging the S&P 500 (SPY) return of 16.8%. The stock traded at $3.13 on October 16, 2026, down 83.4% versus its 200-day average.

Anbio Biotechnology has no analyst coverage, consensus ratings, or formal price targets reported following its closing price of $3.13 on October 16, 2026. For the trailing twelve months ended March 31, 2026, the company generated diluted earnings per share of $0.15, supported by quarterly earnings growth of 2.8% and revenue growth of 73.9% year over year. No future earnings estimates or upcoming earnings dates are listed for the Frankfurt-based diagnostics provider.

This page is an AI-written research summary of Anbio Biotechnology Class A (NNNN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NNNN income statement, NNNN balance sheet, NNNN key metrics, NNNN chart. See the NNNN stock overview for the latest quote and news.